Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6731145 | 0.91 | SKP2 (0.43) | CYP1A2SKP2SIGMAR1BDKRB2 | |
| SCHEMBL6736827 | 0.90 | SKP2 (0.39) | SKP2BDKRB2 | |
| SCHEMBL6736855 | 0.88 | CYP1A2 (0.46) | CYP1A2CYP2A6MEN1POLBGAA | |
| SCHEMBL6737669 | 0.86 | CNR1 (0.39) | CNR1CNR2NCEH1CYP1A2CYP2A6 | |
| SCHEMBL6738566 | 0.86 | CNR1 (0.39) | CNR1CNR2NCEH1CYP1A2CYP2A6 | |
| SCHEMBL6736746 | 0.84 | CNR1 (0.37) | CNR1CNR2NCEH1CYP1A2CYP2A6 | |
| SCHEMBL6731332 | 0.81 | TLR8 (0.35) | CNR1CNR2NCEH1SKP2ALOX5 | |
| SCHEMBL6735447 | 0.80 | TLR8 (0.40) | CNR1CNR2ALOX5BDKRB2MEN1 | |
| SCHEMBL6741609 | 0.78 | SKP2 (0.36) | SKP2ALOX5SIGMAR1BDKRB2 | |
| SCHEMBL6736230 | 0.78 | SKP2 (0.37) | CYP1A2CYP2A6SKP2SIGMAR1BDKRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6682785-B2 | A FLUOROANTHRACENE COMPOUNDS; HEAT RESISTANCE, RADIATION RESISTANCE, PHOTOSTABILITY | CLARIANT FINANCE (BVI) LIMITED (VG) | 2004-01-27 | — | — | US | disclosed |
| US-20030118749-A1 | A fluoroanthracene compounds; heat resistance, radiation resistance, photostability | CLARIANT INTERNATIONAL LTD. | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030118749-A1 | A fluoroanthracene compounds; heat resistance, radiation resistance, photostability | HSF1, ABCC1, FLNA | CNR1 2742/4885CNR2 3959/4885NCEH1 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.